Time: Thursday, October 26, 2006 at 1 p.m. CET (changed from 2 p.m. CET). Telephone number: +46 8 619 75 40, access code 541875#
Vitrolife participants: Magnus Nilsson, CEO Anna Ahlberg, CFO
The press release for Vitrolife's Q3 report will be released before noon October 26.
Before the conference call, slides will be available at the company web page, www.vitrolife.com, under the section Investors/News (the Swedish page). A recorded version of the presentation will be available for five working days on number +46 8 568 44 159, customer no 8989#, access code 9898#, conference no 101010#.
Queries should be addressed to: Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61. Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.
Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Cell therapy. The Fertility product area works with nutrient solutions (media) and advanced one-time instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Cell therapy product area works with media to enable the use of stem cells for therapeutic purposes.
Vitrolife today has approximately 110 employees and the company's products are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and there are subsidiaries outside Gothenburg, Sweden and in Denver, USA. The Vitrolife share is listed on the Stockholm Stock Exchange's Nordic Small Cap list.
This information was brought to you by Waymaker http://www.waymaker.net
© 2006 Business Wire
